My biography comprehends 2 main parts. My academic background, MD (1963), Internist Certified (1968), Fellow in Critical Care Medicine (1975), Fellow in Cardiovascular Research (1976), bases for Translational Medicine.
In this period, as Founder of the 3rd ICU and Research Laboratory in Venezuela (1971), we developed a novel treatment for hypertensive crisis (1979, IV Chlorpromazine, Book Chapter); as Cardiovascular Research Fellow, my description of RV Infarction and Cardiogenic Shock in clinical and post-operative bypass surgery (Deborah Heart and Lung Young Investigator Award, 1976).
From 1977-1998, as Chief of Department of Medicine at Dr. Adolfo Prince Lara University Hospital, our Research Laboratory, addressing RBC-K physiology and disorder, identified an inherited defect of RBC-K in hypertensives, and half of their healthy normotensive sibling and offspring, suggesting that essential hypertension was a major genetic disease (March 02, 1983).
From 1998-2010, our Joint Research at the University of Michigan (FBBP, NIH) on RBC-K phenotype and gene polymorphisms, introduced aortic stiffness by DynaPulse (ACP) and TBK by BIA, uncovering other physiological alterations in essential hypertension, published in abstracts, articles, book chapters and recognized by awards, US Patents and Inter-Institutional Agreements.
From 1998-present, our Clinical Research Unit have reported systolic aortic PWr, impaired tubular function, nocturnal polyuria (≥1500 m) and decreased TBK and TBW in 67% of hypertensives, improved by Amiloride HCl Dihydrate drug. At the top was the discovery of K-O2 binding by human hemoglobin, altered in hypertensives, and involved on the pathogenesis of essential hypertension and CHD. Finally, evidences that human RBCs are the sole regulator of body K homeostasis, in health and disease states, support novel clinical concepts on Intracellular Potassium Physiology and Disorders.